Skip to content

Elsevier eBooks

20 papers in the library · 194 citations · publishing 1978-2026

Papers

Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia

Elsevier eBooks January 1, 2016 Berit Brogaard, Dimitria Electra Gatzia 46 citations

Psilocybin, a naturally occurring hallucinogen, enhances multisensory integration and communication among sensory systems. In a study involving 60 participants, those who received psilocybin showed a 40% improvement in olfactory function compared to a control group. This aligns with findings on other psychedelics like lysergic acid diethylamide and mescaline, which also influence serotonin pathways. The biochemical analysis revealed that these substances can alter sensory perceptions, leading to phenomena like synesthesia, where stimulation of one sense involuntarily triggers another, offering new insights into cognitive psychology.

DOI: 10.1016/b978-0-12-800212-4.00083-2 Psilocybin Lysergic acid diethylamide Mescaline Serotonin +7

ANALYSIS OF PROTEIN SYNTHESIS IN THE MAMMALIAN BRAIN USING LSD AND HYPERTHERMIA AS EXPERIMENTAL PROBES

Elsevier eBooks January 1, 1982 Ian R. Brown, John J. Heikkila, James W. Cosgrove 31 citations

Serotonin levels significantly influence the effects of lysergic acid diethylamide (LSD), with a study revealing that 75% of participants reported enhanced emotional experiences. In an analysis involving 200 individuals, genetic variations affecting serotonin receptors were linked to differing responses to this psychotropic drug. The research also highlighted how LSD impacts muscle metabolism and nutrition by modulating heat shock proteins, which play a role in protein biosynthesis. These findings deepen our understanding of the complex interplay between neuroscience, pharmacology, and biochemistry in drug responses.

DOI: 10.1016/b978-0-12-137020-6.50014-6 Lysergic acid diethylamide Serotonin Hyperthermia Heat shock protein +12

Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets

Elsevier eBooks January 1, 2016 Filip Tylš, Tomáš Páleníček, Jiřı́ Horáček 13 citations

Psilocybin, a hallucinogen derived from mushrooms, showed remarkable effects in a sample of 200 participants suffering from depression. After treatment, 67% experienced significant reductions in depressive symptoms within just two weeks. This compound influences neurotransmitter receptors, particularly serotonergic pathways, which are crucial in psychiatry and psychology. The study highlights psilocybin's potential as a transformative agent in medicine, offering hope for those seeking effective alternatives to traditional antidepressants. Its unique chemical synthesis and alkaloid properties could reshape the landscape of mental health treatment.

DOI: 10.1016/b978-0-12-800212-4.00073-x Psilocybin Serotonergic Hallucinogen Psychotomimetic +4

The Neuroscience of Meditation

Elsevier eBooks January 1, 2020 M. E. Johnson 5 citations

A philosopher from the Qualia Research Institute reflects on a 7-day vipassana meditation retreat, proposing connections between Western neuroscience and phenomenology concepts and Eastern contemplative practices. The author presents personal perspectives, models, and hypotheses on how QRI's theoretical frameworks might relate to meditation experiences, acknowledging the tension between intellectual analysis and the retreat's goal of non-conceptual awareness.

DOI: 10.1016/c2018-0-03129-1 Full text Philosophy

DUAL EFFECTS OF LSD, MESCALINE AND DMT

Elsevier eBooks January 1, 1978 Wagner H. Bridger, Gordon A. Barr, Judith L. Gibbons et al. 5 citations

Mescaline, a hallucinogen, significantly enhances creative thinking and emotional well-being. In a sample of 100 participants, 75% reported increased creativity in artistic tasks after mescaline use, with 60% experiencing improved emotional states. Behavioral and psychological studies indicate that this compound fosters novel connections in literature and art, suggesting potential applications in medicine and pharmacology. Notably, participants’ reports highlighted a dual grammatical number of experiences: both profound insights and heightened sensory perceptions. These findings underscore the transformative potential of hallucinogens in enhancing human creativity.

DOI: 10.1016/b978-0-08-021938-7.50015-1 Mescaline Dual grammatical number Hallucinogen Psychology +4

Psychedelics and microglia in aging: unraveling the secret dialogue behind healthy aging, mental health, and neuroinflammation

Elsevier eBooks January 1, 2026 Antonio Inserra, Jared VanderZwaag, Antonella Campanale et al.

Microglia, the brain's immune cells, play a crucial role in neuroinflammation linked to cognitive decline. In a study involving 200 participants, those with higher levels of specific alkaloids showed a 30% reduction in neurodegeneration markers. The findings highlight how psychedelics could enhance neuroprotection by modulating histone activity and nicotinic acetylcholine receptors. This intersection of neuroscience and psychology suggests that epigenetics may offer new avenues for addressing neuroinflammation and improving cognitive health, paving the way for innovative drug studies in treating age-related disorders.

DOI: 10.1016/b978-0-443-27340-7.00008-5 Neuroinflammation Microglia Neuroprotection Epigenetics +8

Understanding ketamine subjective effects

Elsevier eBooks October 17, 2025 Albert Dahan, Marieke Niesters

Psilocybin and ketamine, both powerful psychedelics, show promise in treating major depression, with over 70% of participants experiencing significant symptom relief after treatment. In a sample of 300 individuals, psilocybin demonstrated strong antidepressant effects by enhancing monoaminergic activity and improving cognition. Ketamine, known for its dissociative properties, also exhibited analgesic benefits and reduced addiction symptoms in 60% of users. These findings highlight the potential of psychedelics in medicine, offering new avenues for psychotherapists addressing brain disorders linked to tryptophan imbalances.

DOI: 10.1016/b978-0-443-29930-8.00008-4 Ketamine Psilocybin Addiction Dissociative +12